Clinical Trial

Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

Study acronym: FUTURE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The FUTURE trial is a prospective, multicentre, exploratory, open-label phase II platform trial. Its goal is to evaluate the efficacy, feasibility and safety of futibatinib combined with immunotherapeutic, targeted or chemotherapeutic agents in colorectal and other solid tumors and to additionally identify biomarkers that correlate with clinical outcome.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-12-05; most recent amendment 2025-12-23.
Status change: Not Yet Recruiting → Recruiting 2025-12-23
Trial Details
NCT Number NCT06722183
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler
Conditions Colorectal Cancer
Enrollment 33 participants
Start Date 2025-12-16
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-24